The Infectious Diseases Society of America (IDSA) published guidelines for the diagnosis and treatment of prosthetic joint infections and native vertebral osteomyelitis in 2013 and 2015, respectively. Both guidelines discuss pathogen-specific intravenous antimicrobial therapy. For the management of penicillin-susceptible Enterococcus species, the expert panel recommends penicillin G 20–24 million units IV every 24 hours continuously or in 6 divided doses or ampicillin sodium 12 g IV every 24 hours continuously or in 6 divided doses as preferred treatment options. These recommendations offer clear guidance for managing these challenging infections. [1], [2]
A 2023 stability assessment investigated ampicillin sodium at two concentrations (15 mg/mL and 50 mg/mL) in 250 mL polyisoprene elastomeric infusion pumps (EIPs), with the goal of informing their suitability for outpatient parenteral antimicrobial therapy (OPAT). Ampicillin diluted in 0.9% sodium chloride was analyzed under refrigerated storage (4 ± 1 °C) and under simulated real-life conditions using two ambient temperatures (25 °C and 32 °C), both with and without a cooling device. The analytical method employed was a validated ultra-high-performance liquid chromatography (UHPLC) assay with photodiode array detection at 225 nm, utilizing a BEH C18 column and a methanol/acetonitrile-based mobile phase. At each time point, ampicillin samples were diluted and injected in triplicate, with stability defined as ≥90% of baseline concentration. Physical stability was concurrently assessed through pH and visual appearance parameters. Results demonstrated that at 15 mg/mL, ampicillin remained chemically stable (>90% of baseline) for up to 72 hours under refrigeration, and for an additional 24 hours at 25 °C regardless of cooling device use. In contrast, the 50 mg/mL solution degraded rapidly, falling below 90% after 24 hours even under refrigerated conditions, and below 85% at 25 °C after 8 hours of ambient exposure, despite the use of a cooling device. At 32 °C, only the 15 mg/mL formulation preserved ≥90% concentration for up to 20 hours when combined with temperature modulation through the cooling system. Continuous temperature monitoring confirmed that the cooling device had limited effectiveness beyond the initial few hours of ambient storage. Throughout all conditions tested, no significant pH shifts or visible precipitation occurred. These results provide compelling evidence that low-concentration (15 mg/mL) ampicillin in elastomeric pumps is a viable candidate for OPAT implementation, while higher concentrations may be unsuitable due to subtherapeutic degradation profiles. [3]